Cell lines and media for difficult to culture tumour types
Aids R&D initiatives to advance precision medicine.
AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumour types where no models may exist.
Alex Sim, Managing Director at Amsbio said: "Our new partnership with Cellaria Biosciences expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
Directly derived from patient tumours without any genetic manipulation, these new products provide the assurance of primary cells with long-term reproducibility and scalability. Unlike traditional protocols for cell line creation, these cancer models eliminate the possibility of large-scale cellular adaptation through culture and genetic drift.
Beneficially the cancer cell models are stable and show a high level of agreement to the original tumour genotype through 150 passages via SNP analysis. In addition, the cell models exhibit predictable growth rates and stable proteomic expression. Furthemore, these models come fully consented, fully documented, and subject to extensive quality control.
The quality control of the cancer cell models includes screened for all major categories of cell contaminants, including mycoplasma, microbial contaminants, viruses, cell line cross-contamination and STR profiling. Lot specific growth rate and protocol data is provided for every customer. Amsbio's extensive quality control process ensures stable growth rate for each lot of Cellaria cell models delivered.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance